Glumetinib

DB15630InvestigationalSmall molecule

Glumetinib is under investigation in clinical trial NCT04270591 (Assess the Anti-tumor Activity and Safety of Glumetinib in Patient With Advanced C-met-positive Non-small Cell Lung Cancer).

Mechanism: Pharmacologically active on Hepatocyte growth factor receptor
Curator reviewed
Formula / weight: C₂₁H₁₇N₉O₂S · 459.49 g/mol (avg)
Also known as: 6-(1-methyl-1h-pyrazol-4-yl)-1-((6-(1-methyl-1h-pyrazol-4-yl)imidazo(1,2-a)pyridin-3-yl)sulfonyl)-1h-pyrazolo(4,3-b)pyridine
Code names: SC-C244

Resolves to

Compound

UNII7JTT036WGXCAS1642581-63-2

Structure

InChIKeyRYBLECYFLJXEJX-UHFFFAOYSA-NSMILESCN1C=C(C=N1)C1=CN2C(C=C1)=NC=C2S(=O)(=O)N1N=CC2=NC=C(C=C12)C1=CN(C)N=C1

Targets

P08581MET

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Glumetinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account